Istanbul, Turkey, January 23, 2017
TRPharm and Leadiant Biosciences Ltd, UK formerly known as Sigma-Tau Rare Disease Ltd, UK announced today that they are adding a new product to their existing distribution relationship within the orphan diseases space. As part of the agreement TRPharm will provide supply for the product as of January 1st, 2017.
Mehmet Göker, General Manager of TRPharm, commented “At TRPharm, we make efforts to meet the needs of the patients and provide them better health services. With this addition we continue to proceed with solid steps, further strengthening our portfolio.
In addition, the expansion of our agreement with Leadiant Biosciences Ltd is a very important milestone for TR Pharm that shows our performance and ambition is meeting the expectation of our partners.””
TRPharm is a pharma start-up focused on innovation with investments into R&D and a cutting edge biotechnological manufacturing capability with the aim of becoming a regional commercial player based out of Turkey.
TRPharm focuses on the launch of new and innovative medicines starting from registration and accomplishment of clinical programs in all phases, as well as building a biotech manufacturing facility in Turkey for the supply of monoclonal antibodies to CIS and MENA region besides the local market. TRPharm has a wide product portfolio, led by oncology, virology, inflammatory and rare diseases.
About Leadiant Biosciences Limited Ltd
Leadiant Biosciences Limited formerly known as Sigma-Tau Rare Disease Ltd is a global pharmaceutical business committed to the development, registration and commercialization of orphan therapeutics. Operations extend through North America and Europe with strategic partnerships established in major emerging markets.